Hi KMBJN, I agree with most of your post and while I do think we need to temper expectations with regards to the pancreatic cancer patients response to Kevetrin, I believe statistics you mention regarding PFS could be a bit misleading. While I take you at your word that those numbers are accurate for pancreataic cancer patients, they probably refer to initial treatments and not for those who failed a treatment and then started a second form of treatment and thus their cancer is growing again. Since one of the requirements for inclusion in the Phase I Kevetrin trial is:
either refractory after standard therapy, or for which no effective curative or surgical treatment options are available
There is a resonable chance that the panceratic cancer patient who had the 4 month stabilization was someone who had already gone thru standard/earlier treatment and now had refractory disease and then achived a second 4 month stabilization. That is the aspect that would make it notable if indeed the patient had failed earlier treatment. No way of knowing but hopefully that's the case.
News 
Market Data 
Discover 
AI
